COST-UTILITY ANALYSIS OF LORLATINIB FOR FIRST-LINE TREATMENT FOR ALK POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN CHINA

被引：0
|
作者：
He, X. [1 ]
Fu, S. [1 ]
机构：
[1] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin, Peoples R China
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE69
引用
收藏
页码：S63 / S63
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [42] Analysis of continuous first-line treatment with docetaxel and carboplatin for advanced non-small cell lung cancer
    Aoki, Takuya
    Ebihara, Akinori
    Yogo, Yurika
    Suemasu, Keiichi
    Sakamaki, Fumio
    ONCOLOGY LETTERS, 2014, 7 (06) : 1771 - 1777
  • [43] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [44] An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer
    Riudavets, Mariona
    Planchard, David
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (03) : 291 - 299
  • [45] Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
    Liu, Jia
    Cao, Lidan
    Wu, Jing
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [46] COST-EFFECTIVENESS OF EML4-ALK GENE TARGETED FIRST-LINE CERITINIB TREATMENT AMONG PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
    Upadhyay, N.
    Atreja, N.
    VALUE IN HEALTH, 2015, 18 (03) : A203 - A203
  • [47] A COST-UTILITY ANALYSIS OF DACOMITINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR EXON 21 L858R SUBSTITUTION MUTATION IN CHINA
    Jin, G.
    Zhao, J.
    Luan, L.
    Dong, P.
    Yang, L.
    VALUE IN HEALTH, 2021, 24 : S215 - S215
  • [48] Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer
    Leprieur, Etienne Giroux
    Wislez, Marie
    BULLETIN DU CANCER, 2016, 103 (02) : 125 - +
  • [49] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [50] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
12345